|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jackson AL, Zhou B and Kim WY: HIF,
hypoxia and the role of angiogenesis in non-small cell lung cancer.
Expert Opin Ther Targets. 14:1047–1057. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nan X, Xie C, Yu X and Liu J: EGFR TKI as
first-line treatment for patients with advanced EGFR
mutation-positive non-small-cell lung cancer. Oncotarget.
8:75712–75726. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong L, Lei D and Zhang H: Clinical
strategies for acquired epidermal growth factor receptor tyrosine
kinase inhibitor resistance in non-small-cell lung cancer patients.
Oncotarget. 8:64600–64606. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nguyen KS, Kobayashi S and Costa DB:
Acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small-cell lung cancers dependent on the
epidermal growth factor receptor pathway. Clin Lung Cancer.
10:281–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma C, Wei S and Song Y: T790M and acquired
resistance of EGFR TKI: A literature review of clinical reports. J
Thorac Dis. 3:10–18. 2011.PubMed/NCBI
|
|
8
|
Regales L, Gong Y, Shen R, de Stanchina E,
Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O,
Mellinghoff IK, et al: Dual targeting of EGFR can overcome a major
drug resistance mutation in mouse models of EGFR mutant lung
cancer. J Clin Invest. 119:3000–3010. 2009.PubMed/NCBI
|
|
9
|
Janjigian YY, Smit EF, Groen HJ, Horn L,
Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, et al:
Dual inhibition of EGFR with afatinib and cetuximab in kinase
inhibitor-resistant EGFR-mutant lung cancer with and without T790M
mutations. Cancer Discov. 4:1036–1045. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim D, Bach DH, Fan YH, Luu TT, Hong JY,
Park HJ and Lee SK: AXL degradation in combination with EGFR-TKI
can delay and overcome acquired resistance in human non-small cell
lung cancer cells. Cell Death Dis. 10:3612019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pan YH, Jiao L, Lin CY, Lu CH, Li L, Chen
HY, Wang YB and He Y: Combined treatment with metformin and
gefitinib overcomes primary resistance to EGFR-TKIs with EGFR
mutation via targeting IGF-1R signaling pathway. Biologics.
12:75–86. 2018.PubMed/NCBI
|
|
12
|
Zhuang H, Bai J, Chang JY, Yuan Z and Wang
P: MTOR inhibition reversed drug resistance after combination
radiation with erlotinib in lung adenocarcinoma. Oncotarget.
7:84688–84694. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang
JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, et al: Gefitinib Plus
chemotherapy versus chemotherapy in epidermal growth factor
receptor mutation-positive non-small-cell lung cancer resistant to
first-line gefitinib (IMPRESS): Overall survival and biomarker
analyses. J Clin Oncol. 35:4027–4034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhuang H, Shi S, Guo Y and Wang Z:
Increase of secondary mutations may be a drug-resistance mechanism
for lung adenocarcinoma after radiation therapy combined with
tyrosine kinase inhibitor. J Cancer. 10:5371–5376. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Muz B, de la Puente P, Azab F and Azab AK:
The role of hypoxia in cancer progression, angiogenesis,
metastasis, and resistance to therapy. Hypoxia (Auckl). 3:83–92.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Majmundar AJ, Wong WJ and Simon MC:
Hypoxia-inducible factors and the response to hypoxic stress. Mol
Cell. 40:294–309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tatum JL, Kelloff GJ, Gillies RJ, Arbeit
JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia
AJ, et al: Hypoxia: Importance in tumor biology, noninvasive
measurement by imaging, and value of its measurement in the
management of cancer therapy. Int J Radiat Biol. 82:699–757. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ziello JE, Jovin IS and Huang Y:
Hypoxia-inducible factor (HIF)-1 regulatory pathway and its
potential for therapeutic intervention in malignancy and ischemia.
Yale J Biol Med. 80:51–60. 2007.PubMed/NCBI
|
|
19
|
Jing X, Yang F, Shao C, Wei K, Xie M, Shen
H and Shu Y: Role of hypoxia in cancer therapy by regulating the
tumor microenvironment. Mol Cancer. 18:1572019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin X, Dai L, Ma Y, Wang J and Liu Z:
Implications of HIF-1α in the tumorigenesis and progression of
pancreatic cancer. Cancer Cell Int. 20:2732020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li H, Zhou S, Li X, Wang D, Wang Y, Zhou C
and Schmid-Bindert G: Gefitinib-resistance is related to BIM
expression in non-small cell lung cancer cell lines. Cancer Biother
Radiopharm. 28:115–123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sharma P, Hu-Lieskovan S, Wargo JA and
Ribas A: Primary, adaptive, and acquired resistance to cancer
immunotherapy. Cell. 168:707–723. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He J, Jin S, Zhang W, Wu D, Li J, Xu J and
Gao W: Long non-coding RNA LOC554202 promotes acquired gefitinib
resistance in non-small cell lung cancer through upregulating
miR-31 expression. J Cancer. 10:6003–6013. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nigro A, Ricciardi L, Salvato I, Sabbatino
F, Vitale M, Crescenzi MA, Montico B, Triggiani M, Pepe S, Stellato
C, et al: Enhanced expression of CD47 is associated with off-target
resistance to tyrosine kinase inhibitor gefitinib in NSCLC. Front
Immunol. 10:31352020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Del Signore A, Gotti C, Rizzo A, Moretti M
and Paggi P: Nicotinic acetylcholine receptor subtypes in the rat
sympathetic ganglion: Pharmacological characterization, subcellular
distribution and effect of pre- and postganglionic nerve crush. J
Neuropathol Exp Neurol. 63:138–150. 2004. View Article : Google Scholar
|
|
27
|
Kim AR, Kim JH, Kim A, Sohn Y, Cha JH, Bak
EJ and Yoo YJ: Simvastatin attenuates tibial bone loss in rats with
type 1 diabetes and periodontitis. J Transl Med. 16:3062018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pacioni S, Rueger MA, Nisticò G, Bornstein
SR, Park DM, McKay RD and Androutsellis-Theotokis A: Fast, potent
pharmacological expansion of endogenous
hes3+/sox2+ cells in the adult mouse and rat
hippocampus. PLoS One. 7:e516302012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kwon TR, Han SW, Kim JH, Lee BC, Kim JM,
Hong JY and Kim BJ: Polydeoxyribonucleotides improve diabetic wound
healing in mouse animal model for experimental validation. Ann
Dermatol. 31:403–413. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Maxwell PH, Dachs GU, Gleadle JM, Nicholls
LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW and Ratcliffe PJ:
Hypoxia-inducible factor-1 modulates gene expression in solid
tumors and influences both angiogenesis and tumor growth. Proc Natl
Acad Sci USA. 94:8104–8109. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Carmeliet P, Dor Y, Herbert JM, Fukumura
D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R,
Maxwell P, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis,
cell proliferation and tumour angiogenesis. Nature. 394:485–490.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin JJ and Shaw AT: Resisting resistance:
Targeted therapies in lung cancer. Trends Cancer. 2:350–364. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao J, Li HR, Jin C, Jiang JH and Ding JY:
Strategies to overcome acquired resistance to EGFR TKI in the
treatment of non-small cell lung cancer. Clin Transl Oncol.
21:1287–1301. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qi M, Tian Y, Li W, Li D, Zhao T, Yang Y,
Li Q, Chen S, Yang Y, Zhang Z, et al: ERK inhibition represses
gefitinib resistance in non-small cell lung cancer cells.
Oncotarget. 9:12020–12034. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Semenza GL: HIF-1 and human disease: One
highly involved factor. Genes Dev. 14:1983–1991. 2000.PubMed/NCBI
|
|
37
|
Chen L, Feng P, Li S, Long D, Cheng J, Lu
Y and Zhou D: Effect of hypoxia-inducible factor-1alpha silencing
on the sensitivity of human brain glioma cells to doxorubicin and
etoposide. Neurochem Res. 34:984–990. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nardinocchi L, Puca R, Sacchi A and
D'Orazi G: Inhibition of HIF-1alpha activity by
homeodomain-interacting protein kinase-2 correlates with
sensitization of chemoresistant cells to undergo apoptosis. Mol
Cancer. 8:12009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hao J, Song X, Song B, Liu Y, Wei L, Wang
X and Yu J: Effects of lentivirus-mediated HIF-1alpha knockdown on
hypoxia-related cisplatin resistance and their dependence on p53
status in fibrosarcoma cells. Cancer Gene Ther. 15:449–455. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo
C, Han S, Liu J, Sun S, Han Z, et al: Hypoxia-inducible factor-1
alpha contributes to hypoxia-induced chemoresistance in gastric
cancer. Cancer Sci. 99:121–128. 2008.PubMed/NCBI
|
|
41
|
Sasabe E, Zhou X, Li D, Oku N, Yamamoto T
and Osaki T: The involvement of hypoxia-inducible factor-1alpha in
the susceptibility to gamma-rays and chemotherapeutic drugs of oral
squamous cell carcinoma cells. Int J Cancer. 120:268–277. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brown LM, Cowen RL, Debray C, Eustace A,
Erler JT, Sheppard FC, Parker CA, Stratford IJ and Williams KJ:
Reversing hypoxic cell chemoresistance in vitro using genetic and
small molecule approaches targeting hypoxia inducible factor-1. Mol
Pharmacol. 69:411–418. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
von Manstein V, Yang CM, Richter D, Delis
N, Vafaizadeh V and Groner B: Resistance of cancer cells to
targeted therapies through the activation of compensating signaling
loops. Curr Signal Transduct Ther. 8:193–202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Unruh A, Ressel A, Mohamed HG, Johnson RS,
Nadrowitz R, Richter E, Katschinski DM and Wenger RH: The
hypoxia-inducible factor-1 alpha is a negative factor for tumor
therapy. Oncogene. 22:3213–3220. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Verduzco D, Lloyd M, Xu L, Ibrahim-Hashim
A, Balagurunathan Y, Gatenby RA and Gillies RJ: Intermittent
hypoxia selects for genotypes and phenotypes that increase
survival, invasion, and therapy resistance. PLoS One.
10:e01209582015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhao Q, Li Y, Tan BB, Fan LQ, Yang PG and
Tian Y: HIF-1α induces multidrug resistance in gastric cancer cells
by inducing miR-27a. PLoS One. 10:e01327462015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Roncuzzi L, Pancotti F and Baldini N:
Involvement of HIF-1α activation in the doxorubicin resistance of
human osteosarcoma cells. Oncol Rep. 32:389–394. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li F, Zhu T, Cao B, Wang J and Liang L:
Apatinib enhances antitumour activity of EGFR-TKIs in non-small
cell lung cancer with EGFR-TKI resistance. Eur J Cancer.
84:184–192. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lu H, Lu Y, Xie Y, Qiu S, Li X and Fan Z:
Rational combination with PDK1 inhibition overcomes cetuximab
resistance in head and neck squamous cell carcinoma. JCI Insight.
4:42019. View Article : Google Scholar
|
|
50
|
Lu H, Liang K, Lu Y and Fan Z: The
anti-EGFR antibody cetuximab sensitizes human head and neck
squamous cell carcinoma cells to radiation in part through
inhibiting radiation-induced upregulation of HIF-1α. Cancer Lett.
322:78–85. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Comerford KM, Wallace TJ, Karhausen J,
Louis NA, Montalto MC and Colgan SP: Hypoxia-inducible
factor-1-dependent regulation of the multidrug resistance (MDR1)
gene. Cancer Res. 62:3387–3394. 2002.PubMed/NCBI
|
|
52
|
Lu CW, Lin SC, Chien CW, Lin SC, Lee CT,
Lin BW, Lee JC and Tsai SJ: Overexpression of pyruvate
dehydrogenase kinase 3 increases drug resistance and early
recurrence in colon cancer. Am J Pathol. 179:1405–1414. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Kim CH, Yoo YD and Lee JC: Gefitinib circumvents
hypoxia-induced drug resistance by the modulation of HIF-1alpha.
Oncol Rep. 21:801–807. 2009.PubMed/NCBI
|
|
54
|
Jin Q, Zhou J, Xu X, Huang F and Xu W:
Hypoxia-inducible factor-1 signaling pathway influences the
sensitivity of HCC827 cells to gefitinib. Oncol Lett. 17:4034–4043.
2019.PubMed/NCBI
|
|
55
|
Hu H, Miao XK, Li JY, Zhang XW, Xu JJ,
Zhang JY, Zhou TX, Hu MN, Yang WL and Mou LY: YC-1 potentiates the
antitumor activity of gefitinib by inhibiting HIF-1α and promoting
the endocytic trafficking and degradation of EGFR in
gefitinib-resistant non-small-cell lung cancer cells. Eur J
Pharmacol. 874:1729612020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jin Q, Zheng J, Chen M, Jiang N, Xu X and
Huang F: HIF-1 inhibitor YC-1 reverses the acquired resistance of
EGFR-mutant HCC827 cell line with MET amplification to gefitinib.
Oxid Med Cell Longev. 2021:66338672021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pore N, Jiang Z, Gupta A, Cerniglia G, Kao
GD and Maity A: EGFR tyrosine kinase inhibitors decrease VEGF
expression by both hypoxia-inducible factor (HIF)-1-independent and
HIF-1-dependent mechanisms. Cancer Res. 66:3197–3204. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lee SH, Koo KH, Park JW, Kim HJ, Ye SK,
Park JB, Park BK and Kim YN: HIF-1 is induced via EGFR activation
and mediates resistance to anoikis-like cell death under lipid
rafts/caveolae-disrupting stress. Carcinogenesis. 30:1997–2004.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Peng XH, Karna P, Cao Z, Jiang BH, Zhou M
and Yang L: Cross-talk between epidermal growth factor receptor and
hypoxia-inducible factor-1alpha signal pathways increases
resistance to apoptosis by up-regulating survivin gene expression.
J Biol Chem. 281:25903–25914. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Swinson DE and O'Byrne KJ: Interactions
between hypoxia and epidermal growth factor receptor in
non-small-cell lung cancer. Clin Lung Cancer. 7:250–256. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tang N, Wang L, Esko J, Giordano FJ, Huang
Y, Gerber HP, Ferrara N and Johnson RS: Loss of HIF-1alpha in
endothelial cells disrupts a hypoxia-driven VEGF autocrine loop
necessary for tumorigenesis. Cancer Cell. 6:485–495. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lee JG and Wu R: Erlotinib-cisplatin
combination inhibits growth and angiogenesis through c-MYC and
HIF-1α in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia.
17:190–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Laughner E, Taghavi P, Chiles K, Mahon PC
and Semenza GL: HER2 (neu) signaling increases the rate of
hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel
mechanism for HIF-1-mediated vascular endothelial growth factor
expression. Mol Cell Biol. 21:3995–4004. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Meng S, Wang G, Lu Y and Fan Z: Functional
cooperation between HIF-1α and c-Jun in mediating primary and
acquired resistance to gefitinib in NSCLC cells with activating
mutation of EGFR. Lung Cancer. 121:82–90. 2018. View Article : Google Scholar : PubMed/NCBI
|
